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Summary
AnAustralian newspaper recently bestowed Ian Frazer
the title of ‘‘God’s gift to women’’ for his research
team’s part in developing a vaccine to help control
cervical cancer. Here Frazer discusses this work and
the science behind the vaccine.
Designed to prevent infection with some types of human
papillomavirus (HPV), a vaccine (Gardasil) recently ap-
proved by the Food and Drug Administration for use in
9- to 26-year-old women in the USA is the first pharma-
ceutical compound specifically developed to prevent
the common human malignancy cervical cancer. An-
other similar product (Cervarix) should become avail-
able next year. These are conventional protein-adjuvant
vaccines, comprising alum adjuvanted viral capsids of
multiple HPV serotypes assembled from recombinant
viral capsid protein. The vaccines, delivered systemi-
cally, induce neutralizing antibody, protecting against
infection with the incorporated HPV serotypes in skin
and at mucosal surfaces. The nature of HPV infection,
the consequent health problems, and the host response
to infection have been defined during vaccine develop-
ment, which has proven a considerable exercise in epi-
demiology and public health research. The considerable
time lag between vaccine deployment and public health
benefit, together with perceived effects of vaccine avail-
ability on human sexual behavior, is currently influenc-
ing vaccine introduction. Nevertheless, HPV vaccines
should eventually eliminate a number of epithelial can-
cers and reduce the annual burden of cancer deaths
globally by 5%–10%.
The Natural History of Human Papillomavirus
Infection
Papillomaviruses (PV) were among the first defined ‘‘fil-
trable agents’’ (McFadyean and Hobday, 1898), and in
the 1930s Peyton Rous showed that the Shope (cotton-
tail rabbit) PV causes epithelial cancer (Kidd et al., 1936).
However, an association of PV with human epithelial
cancer was not suggested until the pioneering work of
Zur Hausen and colleagues in the late 1970s (Zur Hau-
sen, 1977). PV uses epithelial-cell differentiation to un-
dergo its vegetative life cycle, which has proven difficult
to replicate in vitro. Thus, detection of PV in clinical sam-
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without viral antigens, classification of PV types by se-
rology was delayed, and the diversity of PVs, and of their
associated diseases, was unrecognized. PV infections
in cows (bovine PV), dogs (canine oral PV), and rabbits
(cottontail rabbit PV) are mostly self-limiting and are
considered to be relatively trivial. Association with
epithelial cancer was observed for bovine PV-1 and for
cottontail rabbit PV but was not considered to have a
human counterpart because human warts do not turn
malignant.
In the 1850s, an Italian pathologist, Rigoni Stern, sug-
gested that cancer of the womb might have an infectious
etiology, after observations on the greater incidence of
this cancer in prostitutes than in nuns. Various agents,
including herpes viruses, were subsequently consid-
ered as candidates. Human PV had been thought likely
to be a single agent, responsible for skin warts. Molecu-
lar cloning techniques, however, demonstrated a variety
of PVs, falling into what we now recognized as four
broad families (Table 1). Zur Hausen and colleagues pro-
posed (Zur Hausen, 1977) that some PVs might be re-
sponsible for human cervical cancer. They showed
that, distinct from the PVs associated with genital warts,
PVs infecting anogenital skin could be isolated from cer-
vical cancers and cervical-cancer-derived cell lines. Im-
proved methods for detecting PVs via DNA hybridization
allowed extensive epidemiological studies by the Inter-
national Agency for Cancer Research (IARC) and others,
and these studies established that approximately 100%
of cervical cancer, and a percentage of other anogenital
and head and neck cancers, can be attributed to ‘‘high-
risk’’ human PVs.
PV infections resolve more slowly than most viral
infections, as anyone who has watched a favorite wart
is aware. ‘‘High-risk’’ HPV infections persist in the cervix
in 2% of those infected and convey a risk of cancer, and
the fact that they persist more frequently in immunosup-
pressed patients suggests a role for specific immunity in
viral elimination. Two nonstructural PV proteins, E6 and
E7, which substantially alter epithelial-cell replication
and differentiation, continue to be expressed in HPV-
associated cancers. PV infection alters epithelial-cell
growth and differentiation and does not induce cell
death or local inflammation because the mature virion
is shed by epithelial desquamation. Immunological
studies of PV infection subsequent to the recognition
of multiple PV types have shown that natural infection
produces only weak specific serological responses to
the viral capsid and, with the onset of invasive cancer,
to the E7 nonstructural protein (Frazer, 2004). Cell-medi-
ated immune responses to viral nonstructural proteins,
particularly E2, E6, and E7, are associated with regres-
sion of infection. The mechanism of regression remains
uncertain, although there may be clues in the ability of
topically applied imiquimod, an activator of Toll-like
receptor 7 (TLR7) and TLR8 and a promoter of local
inflammation, to induce regression of only those HPV-
associated lesions to which it is applied. Of course,
none of the above information was known when I started
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from Scotland to Australia in 1981.
Compromised Immunity and Genital Disease—My
Introduction to HPV Infection
When I took up a position as a trainee clinical immunol-
ogist with Ian Mackay at the Walter and Eliza Hall insti-
tute in Melbourne Australia in 1981, I initiated a cohort
study of men who had sex with men (the ‘‘Middle
Park’’ cohort study). Undertaken with a family practi-
tioner, Peter Meese, and his colleagues, this study of
persistent hepatitis B virus infection was, before the rec-
ognition of HIV-1, somewhat unexpectedly transformed
into an early study of the natural history of HIV infection
in Australia (Frazer et al., 1986a). A substantial propor-
tion of men in the Middle Park study were immunocom-
promised, meaning that they had reduced numbers of
helper T cells, and we observed that they did not easily
get rid of genital warts. This observation led me to de-
velop an interest in the immunobiology of HPV infection,
which at that time was essentially unknown territory. I
discussed this topic with Gabrielle Medley, a Melbourne
cytopathologist responsible for the highly effective state
cervical-cancer screening program. We were aware of
Zur Hausen’s work demonstrating a possible associa-
tion of HPV infection with cervical cancer. This led us
to start screening the men in the Middle Park study for
cytological evidence of HPV-associated anal precancer.
The increased frequency of anal cytopathology in men
with CD4+ T cell deficiency, a result of what we by then
knew to be HIV infection (Frazer et al., 1986b), convinced
us that helper T cell responses might be important in the
control of HPV infection. After a move to Brisbane,
Queensland in 1985 to take up a position as director of
the immunology service at the Princess Alexandra Hos-
pital, I was fortunate to be able to recruit Robert Tindle,
and together we did much of the early work defining the
immunogenicity of the nonstructural proteins of HPV16,
the virus type most associated with cervical cancer. An-
imal studies demonstrated immunogenicity of an HPV
protein associated with cellular transformation (E7)
(Tindle et al., 1991). It was clear then that human HPV
Table 1. Broad Classification of Human Papillomavirus Infection
and Associated Cancer Risk
1 Cancer risk only in immunosuppressed subjects or in subjects with
the genetic mutation (Ramoz et al., 2002) associated with epidermo-
dysplasia verruciformis.
2 Most commonly associated with anogenital malignancy (from
about 30 ‘‘high risk’’ genital HPV types).immunobiology would be progressed by creation of
HLA-matched cells expressing HPV antigens as targets
for an assay of cell-mediated immunity and by better
animal models of persistent epithelial infection without
inflammation.
A Trip to Cambridge and a Fortuitous Collaboration
In 1989, with the intent of learning how to optimize re-
combinant expression of HPV nonstructural proteins in
mammalian cells, and of making a mouse transgenic
for these proteins, I took a sabbatical visit with Lionel
Crawford and Margaret Stanley, both acknowledged ex-
perts in HPV pathobiology, in the department of Pathol-
ogy in Cambridge, England. The research program kept
me busy with many late nights in the lab, but it was not
as productive as I’d hoped. I found that E7, when over-
expressed in cells, provoked early cell differentiation
and death, without the need for immunological interven-
tion. The E7 transgenic mouse model had to await a fur-
ther sabbatical, in 1993, to the lab of Paul Lambert in
Madison (Frazer et al., 1995). The result was a longstand-
ing collaboration, which has proven extremely useful in
defining the requirements for effective immunotherapy
for persisting epithelial infections. However, the Cam-
bridge visit had one very important outcome: my meet-
ing with Jian Zhou, a Chinese clinical scientist, then
working with Lionel Crawford on expression of HPV
genes in mammalian cells by the use of recombinant
vaccinia virus. He wanted to better understand how
HPV transformed epithelial cells. Together, we came
up with the idea that if PV genes when overexpressed
singly were lethal to cells and natural HPV16 virus was
not available, these problems might be overcome by
construction of an artificial HPV16 papillomavirus, which
would allow regulated expression and study of PV
genes. We thought this might be achieved by packaging
the PV genome in the PV capsid proteins, which we
could use to infect cells in vitro. Indeed, we subse-
quently went on to achieve this (Zhou et al., 1993). How-
ever, at that time both of our visits to Cambridge were
drawing to a close, and I persuaded Jian that we could
work together if he and his wife, Xiao Yi Sun, came to
Brisbane. He agreed, and this proved to be a happy
choice. In late 1990 and early 1991, as part of our strat-
egy for making synthetic HPV16, we demonstrated that
expression of the two viral capsid proteins of HPV16 (L1
and L2) in monkey kidney cells, via a doubly recombi-
nant vaccinia virus, resulted in assembly of virus-like
particles (VLPs), visible with electron microscopy
(Zhou et al., 1991). This was the first convincing demon-
stration that HPV16 could actually form a capsid be-
cause this virus had not been seen with electron micros-
copy in HPV16-associated clinical lesions. To achieve
this, we expressed the major capsid protein of HPV16
(L1) from the second initiation codon in the L1 gene. We
identified this initiation codon by comparing the gene
sequences of the various PV L1 genes then sequenced.
This primitive exercise in comparative genomics was
undertaken with paper and pencil because our only lab
computer was not up to the job. We and others (Rose
et al., 1993; Kirnbauer et al., 1992) subsequently demon-
strated that PV L1 genes of various HPV types, if
expressed with more efficient eukaryotic expression
systems, would self assemble into viral capsids (VLPs)
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181Figure 1. Distribution of L1 Sequence Variation in 49 HPV Types
The crystal structure of an L1 pentamer, 72 of which together comprise the HPV virus-like particle, is shown from various angles. Positions that
are highly variable between HPV genotypes are red, fully conserved positions are blue, and positions of intermediate variation are white.
(A) Seen from the side and showing conservation of the regions of interaction between pentamers.
(B) Seen from outside the viral capsid and showing the hypervariability of the interface of the pentamer with the outside world.
(C) Seen from within the capsid and showing conservation of the interior of the pentamer.
Figure reprinted from (Chen et al., 2000).without L2, albeit with somewhat reduced efficiency. L1
VLPs are deficient in the ability to package viral DNA,
and they form the basis of the VLP-based vaccines de-
signed to prevent HPV infection. Of course, for the pro-
duction of infectious virions we needed L2, with which
viral episomes could be packaged with reasonable effi-
ciency to make infectious virus, although better tech-
niques for producing infectious pseudovirions have sub-
sequently been developed by others (Buck et al., 2005).
Immune Responses to Human PV and to Human
PV Virus-like Particles
PVs are genetically stable double stranded DNA viruses,
and comprise over 200 largely immunologically distinct
genotypes. Because high-risk genital PV infections
(although so common that for practical purposes they
can be regarded as universal) are frequently sub clinical,
it remains unclear whether natural immunity induced by
infection protects against subsequent viral challenge.
This supposition can, however, be inferred for the PV ge-
notypes associated with visible skin and genital warts,
as skin warts are commonly a problem of childhood,
and genital warts of the first few years of sexual activity.
The basis of protection remains unclear. For the com-
mon human genital PV types, humoral immune re-
sponses after natural infection are largely directed to
conformational determinants of the major capsid pro-
tein L1, are PV type-specific, and are weak and slow to
appear, with only 50% of subjects seroconverting,
mostly by one year after infection (Carter et al., 1996).
Thus, antibody naturally induced by PV infection may
not be the sole means of protecting against further infec-
tion. Cows are protected by prior (resolved) bovine PV-1
infection against further viral challenge, and could also
be protected against bovine PV-1 challenge by prior im-
munization with formalized virions prepared from cow
warts (Campo, 1994). Protection was associated withantibody that could bind to bovine PV1 virions. Similar
results were obtained for canine oral PV, which infects
oral mucosa (Suzich et al., 1995). The canine oral PV
model showed that VLPs could induce protection, which
could be transferred to another animal by the immuno-
globulin fraction of serum, whereas denatured VLPs
induced immunity to L1 but not to conformational deter-
minants, and no protection. These results suggested
that vaccines to prevent human PV based on VLPs
would likely be successful if they induced neutralizing
antibody. However, the human PV infections of interest
are of genital mucosal surfaces and the possibility re-
mained that a strong local mucosal immune response
would be required for protection. B cell epitopes of the
native virions were mapped by monoclonal antibodies
developed against VLPs or virions (Christensen et al.,
1996). Despite the extensive amino acid sequence
homology (>80%) between the major capsid proteins
of the different PV, each PV genotype turned out to be
a largely distinct serotype, at least as far as antibodies
raised against the native virus structure are concerned.
Resolution of the crystal structure of the L1 capsid pro-
tein assembled into a mini-VLP (Figure 1) demonstrated
that the peptide domains comprising the internal struc-
ture of the correctly folded L1 protein, and which interact
with other L1 proteins to form the capsomer, are highly
conserved, whereas the variability between PV types
maps to the domains on the external face of the virion
(Chen et al., 2000; Carter et al., 2006). Some cross reactiv-
ity between closely related genotypes (6 and 11, 16 and
31, 18 and 45) could be predicted from the monoclonal
antibody studies and the mapping of cross-reactive epi-
topes for these types to likely surface sites on the virion.
Clinical Trials—Assays, Endpoints, and Findings
Two vaccines derived from the VLP technology de-
scribed above are currently being trialed worldwide.
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produced from recombinant yeast and correspond to
two human PV types (HPV16 and HPV18) responsible
for about 70% of cervical cancer and two types (HPV6
and HPV11) responsible for >90% of genital warts. Cer-
varix, produced by Glaxo Smith Kline (GSK), includes
VLPs that are produced in insect cells via recombinant
baculovirus and that correspond to HPV16 and HPV18.
The Merck vaccine is adjuvanted with aluminum hydrox-
ide gel (‘‘alum’’), and the GSK vaccine is adjuvanted
with alum and monophosphoryl Lipid A. Antibody is
likely to be the mode of protection against infection
induced by vaccination, although this has yet to be for-
mally established because the vaccines to date have
proven to be 100% effective in clinical trials, and there-
fore no correlative marker of protection has been de-
fined. Furthermore, VLP vaccines induce complex im-
mune responses against multiple conformational and
linear epitopes of the L1 protein. Assays for antibody
fall into three categories: competitive immunoassays
where serum is used to displace one or a cocktail of
monoclonal antibodies of defined specificity from
VLPs, conventional enzyme-linked immunoassays that
use VLP substrates, and pseudovirion neutralization
assays where inhibition by serum of binding and uptake
of VLP capsids into reporter cells is measured. Assays
for PV capsid antibody are not standardized, although
the World Health Organization (WHO) is developing a
reference serum to assist in this process (Ferguson
et al., 2006). Results to date indicate that, to a good
approximation, each of the assays similarly ranks the
magnitude of the total VLP-specific immune responses
induced by vaccination of human subjects with human
PV16 VLPs. However, it is not clear whether particular
specificities of antibody to conformational determinants
on the virus are necessary for neutralization or whether
the different immunoassays are similarly comparable
for immune responses induced by other human PV
types.
Natural immunity to PV infection in humans is com-
plex, with a role for innate immune responses, as well
as cell-mediated immune responses to viral nonstruc-
tural proteins. Protection against reinfection with PV
seems solid in those with congenital antibody defi-
ciency, suggesting that cell-mediated immunity as well
as antibodies may play a role in protecting against rein-
fection, and VLPs induce cellular as well as humoral
immune responses. Both commercially produced vac-
cines produce antibody responses 10- to 50-fold greater
than those that follow natural infection. Use of mono-
phosphoryl lipid A adjuvant increases the titer of total
VLP-specific antibody, but even VLPs delivered without
adjuvant are potent immunogens in humans, presum-
ably because of the crystalline arrays of B cell deter-
minants presented by the VLPs. Perhaps surprisingly,
VLP-specific antibody in genital secretions in humans
and in animals after vaccination is predominantly of
the IgG class, and this together with the protection at
mucosal surfaces conveyed by passively transferred
serum immunoglobulin in the canine oral papillomavirus
model, which would not include IgA with secretory
piece, suggests that development of mucosal IgA re-
sponses may not be particularly important for protection
against mucosal PV infection after vaccination.Several clinical trials of the two commercial vaccines
have been undertaken in 18- to 26-year-old sexually ac-
tive women. These trials were reviewed recently (Lowy
and Schiller, 2006) and have shown that the vaccines
are 100% effective at preventing not only infection with
the high-risk human PVs incorporated in the vaccines
but also at preventing the resulting cervical precancer
lesions and external anogenital lesions, including genital
warts attributable to the vaccine incorporated human PV
strains. For both the Merck (Villa et al., 2006) and the
GSK (Harper et al., 2006) vaccines, antibody responses
are almost universal among immunized subjects previ-
ously naı¨ve to the relevant PV type. Peak antibody re-
sponses 2–6 months after three immunizations gradu-
ally fall over the first two years and then plateau at an
amount about 10–20 times the average observed in
response to natural infection, with constant amounts
observed at least over the next three years. The reason
for the observed persistence of antibody is unclear.
VLPs are highly immunogenic repetitive arrays of cap-
somers, immunogenic without adjuvant, and relatively
stable, and they may persist and present antigen for
many years after immunization. Alternatively, natural
boosting after repeated exposure to infection may main-
tain antibody titer. Data from a cohort of younger women
show that the initial titer of antibody after immunization
of prepubertal women is about three times higher
than that observed in postpubertal subjects (http://
www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222b-
index.htm). Follow-up on this cohort, presumably
mostly not exposed to virus, should clarify whether the
maintained response reflects boosting through natural
exposure. Subjects with prior exposure as measured
by antibody or PV DNA at recruitment have substantially
higher responses to the first vaccine than those naı¨ve at
recruitment.
We and others have established that L1 proteins from
different PV genotypes are sufficiently closely related
in sequence that there are genotype-crossreactive,
cell-mediated immune responses as demonstrated by
cross-sensitization of delayed type-hypersensitivity re-
sponses. The question therefore arises as to whether
the phenomenon of ‘‘original antigenic sin,’’ or the inabil-
ity to respond to novel epitopes on heterotypic virus ob-
served after immunization with a homotypic strain,
might impair immune responses to newly encountered
PV types in those previously immunized with or exposed
to PVs of other types. The almost universal exposure to
the common skin PV types does not prevent a substan-
tial and host-protective antibody response to the B cell
epitopes specific to the vaccine types, suggesting that
the lack of shared B cell epitopes between types may
prevent such immune diversion. Certainly, prior immu-
nity to T cell epitopes of VLPs prevents cell-mediated
immune responses to new epitopes incorporated into
the VLP, which may explain the relative failure of natural
immune responses to genital HPV types to rapidly clear
these infections if prior T helper cell immunity to com-
mon epitopes prevents generation of new cytotoxic T
cell responses.
There are several unresolved issues concerning vac-
cine efficacy. Two of particular importance are the con-
sequence for existing PV infection of immunization with
VLPs of the corresponding type and the extent to which
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related PV types, as defined by monoclonal antibodies,
might result in clinical protection. We observed that
VLPs delivered without adjuvant were immunogenic in
human PV6-infected patients with genital warts and, in
an open label study, that regression of wart lesions
in persistently infected individuals was more common
than might be expected from historic controls (Zhang
et al., 2000). This observation suggested that HPV
VLPs delivered without adjuvant might induce a thera-
peutic immune response; this hypothesis is now being
tested in a randomized placebo-controlled blinded
study in China and Australia. The data from the prophy-
lactic vaccine studies using alum adjuvanted VLPs sug-
gest that there are no marked adverse consequences
from immunizing currently infected subjects. There
may be some therapeutic effect of VLP administration
for infected subjects that have not yet made an immune
response but none for those with persisting infection
associated with measurable humoral immunity. The
crossreactivity of the closely related human PV types
suggested by epitope-mapping studies has been con-
firmed clinically for human PV18 and human PV45 in
that the PV16 and PV 18 vaccine gives good short-
term protection against PV45 but not against other,
less-related types (Harper et al., 2006).
Controversies, Intellectual Property, and Access
in the Developing World
Medical interventions impacting human sexuality have
always been controversial, and there has been substan-
tial ‘‘evidence-free’’ public debate about whether ad-
ministration of a vaccine designed to prevent one sexu-
ally transmitted infection might encourage earlier onset
of, or more frequent, sexual intercourse. Fortunately, the
optimal age to immunize with the PV vaccine has turned
out to be an immunological rather than a moral issue, as
discussed above. The FDA recommendation for the
Merck vaccine is for administration to 9- to 26-year-old
women to prevent anogenital precancer and genital
warts. The two commercial vaccines incorporate intel-
lectual property of varied nature and diverse ownership,
and despite several granted patents and a four-way pat-
ent interference in the USA, intellectual-property issues
remain unresolved in the USA and several other jurisdic-
tions. However, the companies producing vaccines
have entered into crosslicensing agreements designed
to ensure that their respective products will not infringe
on the patents to which the other has license.
Cervical cancer is predominantly a disease of the
developing world, with >250,000 deaths per annum. De-
ployment of a vaccine to prevent cervical cancer in the
developing world poses logistic, financial, and immuno-
logical challenges. Delivery of a vaccine outside of the
usual schedules of the expanded vaccine initiative
(from 0–2 years) will require specific infrastructure and
will attempt to reach a population not currently ac-
cessed by any public health initiatives. The price of the
Merck vaccine in the USA is $360. However, both vac-
cine companies have indicated that they will introduce
differential pricing for the developing world, as is cur-
rently the case for hepatitis B vaccines. Additionally,
the Program for Appropriate Technology in Health
(PATH) and the WHO are developing recommendationsfor possible vaccine-delivery programs for the develop-
ing world, and alternate vaccines based on bacterial
recombinant L1 pentamers, possibly easier to manufac-
ture in the developing world, are being developed (Yuan
et al., 2001). However, it will be necessary to evaluate
field effectiveness of the vaccines in the developing
world, particularly in view of the malnutrition, endemic
malaria, and adolescent iron deficiency, each of which
impact the development of new immune responses
and are concerns in many countries with a high preva-
lence of HPV infection and cervical cancer. A large vac-
cine project underway in Guanacaste, Puerto Rico as
a joint initiative between GSK and the National Institutes
of Health may help to address these issues, and similar
demonstration projects are being planned elsewhere,
including Vanuatu.
Conclusion
The HPV and immunology research communities can
take credit for the development of the world’s first vac-
cine to prevent a specific cancer. It would be a most
satisfying outcome from my involvement in HPV immu-
nology research to see the vaccines effectively de-
ployed in the developing world within our lifetimes.
Successful delivery to the developing world should
show the way for introduction of further vaccines to pre-
vent sexually transmitted infections, as well as common
infections rarely responsible for cancer. The PV vaccine
is only the second licensed vaccine to use recombinant-
DNA technology to produce the antigenic ingredient, but
it will surely not be the last.
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